FMO2

Summary

FMO2 (flavin containing dimethylaniline monoxygenase 2, HGNC:3770) is a protein-coding gene on chromosome 1q24.3, encoding Flavin-containing monooxygenase 2 (Q99518). Catalyzes the oxidative metabolism of numerous xenobiotics, including mainly therapeutic drugs and insecticides that contain a soft nucleophile, most commonly nitrogen and sulfur and participates to their bioactivation.

This gene encodes a flavin-containing monooxygenase family member. It is an NADPH-dependent enzyme that catalyzes the N-oxidation of some primary alkylamines through an N-hydroxylamine intermediate. However, some human populations contain an allele (FMO2*2A) with a premature stop codon, resulting in a protein that is C-terminally-truncated, has no catalytic activity, and is likely degraded rapidly. This gene is found in a cluster with other related family members on chromosome 1. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 2327 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 4 total
• Druggable target: yes
• MANE Select transcript: NM_001460

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3770
Approved symbol	FMO2
Name	flavin containing dimethylaniline monoxygenase 2
Location	1q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000094963
Ensembl biotype	protein_coding
OMIM	603955
Entrez	2327

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron, 1 nonsense_mediated_decay

ENST00000209929, ENST00000462643, ENST00000483192, ENST00000488431, ENST00000489354, ENST00000493513, ENST00000529935, ENST00000895513, ENST00000895514, ENST00000945245

RefSeq mRNA: 3 — MANE Select: NM_001460 NM_001301347, NM_001365900, NM_001460

CCDS: CCDS1293

Canonical transcript exons

ENST00000209929 — 9 exons

Exon	Start	End
ENSE00001321274	171208794	171212686
ENSE00001823058	171185300	171185359
ENSE00003536750	171207718	171207790
ENSE00003541886	171193335	171193523
ENSE00003549156	171199346	171199488
ENSE00003580370	171196649	171196811
ENSE00003604976	171205279	171205634
ENSE00003610243	171185708	171185845
ENSE00003642194	171203865	171204064

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 99.08.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.4208 / max 161.6560, expressed in 177 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6596	1.4208	177

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pericardium	UBERON:0002407	99.08	gold quality
right lung	UBERON:0002167	98.93	gold quality
lower lobe of lung	UBERON:0008949	98.69	gold quality
descending thoracic aorta	UBERON:0002345	97.95	gold quality
mammary duct	UBERON:0001765	97.82	gold quality
thoracic aorta	UBERON:0001515	97.66	gold quality
ascending aorta	UBERON:0001496	97.58	gold quality
epithelium of mammary gland	UBERON:0003244	96.50	gold quality
vena cava	UBERON:0004087	96.48	gold quality
esophagus squamous epithelium	UBERON:0006920	96.41	gold quality
epithelium of esophagus	UBERON:0001976	96.19	gold quality
upper lobe of lung	UBERON:0008948	95.70	gold quality
upper lobe of left lung	UBERON:0008952	95.59	gold quality
lung	UBERON:0002048	95.40	gold quality
mammary gland	UBERON:0001911	95.29	gold quality
thoracic mammary gland	UBERON:0005200	95.28	gold quality
adipose tissue of abdominal region	UBERON:0007808	94.66	gold quality
omental fat pad	UBERON:0010414	94.59	gold quality
peritoneum	UBERON:0002358	94.58	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.43	gold quality
adipose tissue	UBERON:0001013	94.26	gold quality
esophagus mucosa	UBERON:0002469	94.18	gold quality
coronary artery	UBERON:0001621	94.03	gold quality
left coronary artery	UBERON:0001626	94.03	gold quality
cardiac atrium	UBERON:0002081	94.00	gold quality
right atrium auricular region	UBERON:0006631	93.82	gold quality
myocardium	UBERON:0002349	93.67	gold quality
aorta	UBERON:0000947	93.65	gold quality
superficial temporal artery	UBERON:0001614	93.43	gold quality
tongue	UBERON:0001723	93.43	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-126	yes	1881.07
E-GEOD-130148	yes	794.02
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

144 targeting FMO2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-574-5P	100.00	66.01	989
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-590-3P	99.96	74.34	6478

Literature-anchored findings (GeneRIF, showing 8)

• analysis of flavin-containing monooxygenase isoform 2 (FMO2) polymorphisms in Hispanics (PMID:15864117)
• analysis of how the functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa (PMID:18794725)
• Characterization of sulfoxygenation and structural implications of human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K. (PMID:19420133)
• study provides an evidence for the existence of an evolutionary adaptation to an ancient disease based on an ancestral genetic variant acting in a FMO2 haplotypic framework in Ethiopian populations (PMID:28981537)
• The functional FMO2(427Q) isoform was active against nicotine; the truncated FMO2(Q472stop) isoform exhibited no enzyme activity. (PMID:30381441)
• Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. (PMID:36114029)
• Flavin containing monooxygenase 2 regulates renal tubular cell fibrosis and paracrine secretion via SMURF2 in AKI-CKD transformation. (PMID:37800598)
• Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer. (PMID:37963835)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fmo2	ENSMUSG00000040170
rattus_norvegicus	Fmo2	ENSRNOG00000003510
caenorhabditis_elegans		WBGENE00001476
caenorhabditis_elegans		WBGENE00001478
caenorhabditis_elegans		WBGENE00001480
caenorhabditis_elegans	C01H6.4	WBGENE00007254
caenorhabditis_elegans	C46H11.2	WBGENE00016728

Paralogs (5): FMO3 (ENSG00000007933), FMO1 (ENSG00000010932), FMO4 (ENSG00000076258), FOXRED2 (ENSG00000100350), FMO5 (ENSG00000131781)

Protein

Protein identifiers

Flavin-containing monooxygenase 2 — Q99518 (reviewed: Q99518)

Alternative names: Dimethylaniline oxidase 2, FMO 1B1, Pulmonary flavin-containing monooxygenase 2

All UniProt accessions (3): Q99518, A0A0D9SFZ0, A0A0D9SG76

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the oxidative metabolism of numerous xenobiotics, including mainly therapeutic drugs and insecticides that contain a soft nucleophile, most commonly nitrogen and sulfur and participates to their bioactivation. Specifically catalyzes S-oxygenation of sulfur derived compounds such as thioureas-derived compounds, thioetherorganophosphates to their sulfenic acid. In vitro, catalyzes S-oxygenation of the second-line antitubercular drugs thiacetazone (TAZ) and ethionamide (ETA), forming a sulfinic acid and a carbodiimide via a postulated sulfenic acid intermediate. Also catalyzes S-oxygenation of the thioether-containing organophosphate insecticides, phorate and disulfoton.

Subcellular location. Microsome membrane. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in lung (at protein level). Expressed predominantly in lung, and at a much lesser extent in kidney. Also expressed in fetal lung, but not in liver, kidney and brain.

Polymorphism. The sequence shown is that of the allele FMO21. FMO22A is the major allele in the human population, however it encodes a truncated and catalytically inactive protein. FMO22A occurs in essentially 100% of Caucasians and Asians. FMO21 is present at a frequency of approximately 4% to 13% in the sample of population of African descent.

Similarity. Belongs to the FMO family.

RefSeq proteins (3): NP_001288276, NP_001352829, NP_001451* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000960	Flavin_mOase	Family
IPR002254	Flavin_mOase_2	Family
IPR020946	Flavin_mOase-like	Family
IPR036188	FAD/NAD-bd_sf	Homologous_superfamily
IPR050346	FMO-like	Family

Pfam: PF00743

Enzyme classification (BRENDA):

• EC 1.14.13.8 — flavin-containing monooxygenase (BRENDA: 30 organisms, 458 substrates, 77 inhibitors, 260 Km, 123 kcat entries)

Substrate kinetics (BRENDA)

72 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
METHIMAZOLE	0.007–0.5758	18
TAMOXIFEN	0.0013–0.121	15
INDOLE	0.005–0.9	13
BENZYDAMINE	0.0186–0.0659	11
ETHIONAMIDE	0.104–2.131	10
METHYL P-TOLYL SULFIDE	0.0048–10.2	10
FENTHION	0.145–0.351	9
MERCAPTOIMIDAZOLE	0.018–0.0527	9
NADPH	0.0031–0.132	9
TRIMETHYLAMINE	0.0015–0.58	9
SULINDAC SULFIDE	0.0101–0.0163	8
CHLORPROMAZINE	0.022–0.08	7
IMIPRAMINE	0.0047–0.02	7
L-METHIONINE	2.8–48	6
10-[(N,N-DIMETHYLAMINOOCTYL)-2-(TRIFLUOROMETHYL)	15–38	5

UniProt features (23 total): sequence variant 11, binding site 6, initiator methionine 1, chain 1, cross-link 1, transmembrane region 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99518-F1	95.26	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (6): 9–13; 32; 40–41; 60–61; 61–62; 195–198

Post-translational modifications (2): 492, 2

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-217271	FMO oxidises nucleophiles

MSigDB gene sets: 146 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, GOBP_LIPID_MODIFICATION, REACTOME_BIOLOGICAL_OXIDATIONS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_PAIRED_DONORS_WITH_INCORPORATION_OR_REDUCTION_OF_MOLECULAR_OXYGEN, GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_NADPPLUS_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_MONOCARBOXYLIC_ACID_METABOLIC_PROCESS, GOBP_KETONE_METABOLIC_PROCESS, GOBP_REGULATION_OF_FATTY_ACID_METABOLIC_PROCESS, GOBP_NUCLEOBASE_CONTAINING_SMALL_MOLECULE_METABOLIC_PROCESS, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_REGULATION_OF_KETONE_METABOLIC_PROCESS, GOBP_TOXIN_METABOLIC_PROCESS

GO Biological Process (7): obsolete organic acid metabolic process (GO:0006082), NADP+ metabolic process (GO:0006739), xenobiotic metabolic process (GO:0006805), toxin metabolic process (GO:0009404), negative regulation of fatty acid oxidation (GO:0046322), oxygen metabolic process (GO:0072592), energy homeostasis (GO:0097009)

GO Molecular Function (5): N,N-dimethylaniline monooxygenase activity (GO:0004499), flavin adenine dinucleotide binding (GO:0050660), NADP binding (GO:0050661), monooxygenase activity (GO:0004497), oxidoreductase activity (GO:0016491)

GO Cellular Component (3): endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020), endoplasmic reticulum (GO:0005783)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Phase I - Functionalization of compounds	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metabolic process	2
purine nucleotide metabolic process	1
nicotinamide nucleotide metabolic process	1
cellular response to xenobiotic stimulus	1
secondary metabolic process	1
fatty acid oxidation	1
negative regulation of fatty acid metabolic process	1
regulation of fatty acid oxidation	1
multicellular organismal-level homeostasis	1
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen	1
nucleotide binding	1
anion binding	1
adenyl nucleotide binding	1
oxidoreductase activity	1
catalytic activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1894 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FMO2	ZNF888	P0CJ79	398
FMO2	ABCC2	Q92887	392
FMO2	LINC03043	A4D0Y5	380
FMO2	CYP2F1	P24903	350
FMO2	CCS	O14618	346
FMO2	ADH1B	P00325	335
FMO2	RHBDL2	Q9NX52	324
FMO2	SNTN	A6NMZ2	320
FMO2	CYP2S1	Q96SQ9	320
FMO2	TMEM212	A6NML5	318
FMO2	CYGB	Q8WWM9	314
FMO2	NAT2	P11245	307
FMO2	SVEP1	Q4LDE5	304
FMO2	FAM216B	Q8N7L0	304
FMO2	TSPAN19	P0C672	303

IntAct

6 interactions, top by confidence:

A	B	Type	Score
FMO2	GNB2	psi-mi:“MI:0915”(physical association)	0.400
FMO2	STK38L	psi-mi:“MI:0915”(physical association)	0.400
FMO2	bipA	psi-mi:“MI:0915”(physical association)	0.370
ilvC2	FMO2	psi-mi:“MI:0915”(physical association)	0.000
	FMO2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (4): GNB2 (Affinity Capture-MS), STK38L (Affinity Capture-MS), FMO2 (Two-hybrid), FMO2 (Affinity Capture-MS)

ESM2 similar proteins: A4IFM3, F4JJJ3, M1BYJ7, O14756, O49312, O54753, O60774, O64489, O88451, P16549, P17635, P17636, P31512, P31513, P32417, P36365, P36366, P36367, P49109, P49326, P49328, P50170, P50285, P97501, P97872, Q01740, Q04799, Q28505, Q3T001, Q5REK0, Q6IRI9, Q7YS44, Q8HYJ9, Q8HZ69, Q8HZ70, Q8K2I3, Q8K4B7, Q8K4C0, Q8SPQ7, Q8VHG0

Diamond homologs: A0A0B5RNJ4, A3SLM3, A3VVZ4, B6BQB2, B8EIZ7, O23024, O60774, P16549, P17635, P31512, P36365, P36366, P36367, P49326, P50285, P97872, Q01740, Q1V023, Q28505, Q5LT63, Q5REK0, Q6IRI9, Q8HZ69, Q8HZ70, Q8K2I3, Q8K4C0, Q8MP06, Q93Y23, Q99518, Q9C8U0, Q9FWW6, Q9SH25, Q9SS04, Q9SXD5, B8NM63, B8NM73, P32417, Q7YS44, Q8HYJ9, Q8SPQ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

4 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	3
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1160 predictions. Top by Δscore:

Variant	Effect	Δscore
1:171185356:AAAGG:A	donor_loss	1.0000
1:171185357:AAGG:A	donor_loss	1.0000
1:171185358:AGGT:A	donor_loss	1.0000
1:171185359:GGTAA:G	donor_loss	1.0000
1:171185360:G:C	donor_loss	1.0000
1:171185361:T:G	donor_loss	1.0000
1:171185840:TTCA:T	donor_gain	1.0000
1:171185844:AAG:A	donor_loss	1.0000
1:171185845:AG:A	donor_loss	1.0000
1:171185846:G:GG	donor_gain	1.0000
1:171185846:G:T	donor_loss	1.0000
1:171188966:G:GT	donor_gain	1.0000
1:171188969:G:GG	donor_gain	1.0000
1:171193329:CTTCA:C	acceptor_loss	1.0000
1:171193330:TTCAG:T	acceptor_loss	1.0000
1:171193331:TCA:T	acceptor_loss	1.0000
1:171193332:CAGGA:C	acceptor_loss	1.0000
1:171193333:A:AG	acceptor_gain	1.0000
1:171193333:A:T	acceptor_loss	1.0000
1:171193334:G:GG	acceptor_gain	1.0000
1:171193334:GGA:G	acceptor_gain	1.0000
1:171193334:GGAGA:G	acceptor_gain	1.0000
1:171199467:GCTGA:G	donor_gain	1.0000
1:171199468:C:G	donor_gain	1.0000
1:171204046:GCCT:G	donor_gain	1.0000
1:171204065:G:GG	donor_gain	1.0000
1:171207786:GACCT:G	donor_gain	1.0000
1:171207791:G:GG	donor_gain	1.0000
1:171185360:G:GG	donor_gain	0.9900
1:171185844:AA:A	donor_gain	0.9900

AlphaMissense

3547 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:171196765:C:G	C146W	0.990
1:171185834:T:A	W41R	0.989
1:171185834:T:C	W41R	0.989
1:171193394:A:C	K64N	0.985
1:171193394:A:T	K64N	0.985
1:171193389:A:C	S63R	0.983
1:171193391:C:A	S63R	0.983
1:171193391:C:G	S63R	0.983
1:171196700:T:A	W125R	0.979
1:171196700:T:C	W125R	0.979
1:171199378:A:C	S173R	0.979
1:171199380:C:A	S173R	0.979
1:171199380:C:G	S173R	0.979
1:171193410:A:C	S70R	0.977
1:171193412:T:A	S70R	0.977
1:171193412:T:G	S70R	0.977
1:171185836:G:C	W41C	0.975
1:171185836:G:T	W41C	0.975
1:171196755:T:A	V143D	0.975
1:171196763:T:C	C146R	0.974
1:171193393:A:T	K64I	0.972
1:171185803:C:G	C30W	0.971
1:171193443:T:C	F81L	0.971
1:171193445:C:A	F81L	0.971
1:171193445:C:G	F81L	0.971
1:171196764:G:A	C146Y	0.970
1:171203874:A:C	S213R	0.970
1:171203876:C:A	S213R	0.970
1:171203876:C:G	S213R	0.970
1:171185730:C:A	A6D	0.969

dbSNP variants (sampled 300 via entrez): RS1000197051 (1:171201443 CCTT>C), RS1000255077 (1:171211147 A>C), RS1000297217 (1:171201778 A>C), RS1000497999 (1:171192532 C>A,T), RS1000614168 (1:171192747 C>T), RS1000669906 (1:171205942 G>T), RS1000680585 (1:171210286 G>A), RS1000860168 (1:171213174 A>G), RS1000865408 (1:171187122 A>C,G), RS1000942844 (1:171205345 G>C), RS1001214700 (1:171209363 T>C), RS1001268975 (1:171210363 T>G), RS1001294108 (1:171184582 C>A,T), RS1001500898 (1:171212803 A>G), RS1001582474 (1:171209025 G>A)

Disease associations

OMIM: gene MIM:603955 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3542432 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases expression	3
Resveratrol	affects cotreatment, decreases expression	2
Air Pollutants	decreases expression, increases abundance	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	affects expression, decreases expression	2
fluxapyroxad	decreases expression	1
2-phenylphenol	decreases expression	1
testosterone enanthate	affects expression	1
lasiocarpine	decreases expression	1
chlortoluron	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
benzydamine N-oxide	increases chemical synthesis, increases oxidation	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
cyproconazole	decreases expression	1
Docetaxel	affects response to substance	1
Arsenic	increases abundance, decreases expression	1
Benzo(a)pyrene	increases methylation	1
Benzydamine	increases oxidation, increases chemical synthesis	1
Calcitriol	decreases expression	1
Copper	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Ethionamide	increases oxidation	1
Ethylenethiourea	increases oxidation, decreases oxidation	1
Methimazole	decreases oxidation, increases oxidation	1
Plant Extracts	affects cotreatment, decreases expression	1
Propranolol	increases oxidation	1
Silicon Dioxide	decreases expression	1
Smoke	increases abundance, decreases expression	1
Tetrachlorodibenzodioxin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4153816	ADMET	Drug metabolism in human hepatocytes assessed as formation of FMO-mediated N,N-Dimethyl-3-[[5-(3-methyl-2-oxo-1-tetrahydropyran-4-yl-imidazo[4,5c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine oxide	The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one). — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.